Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE-VS
NL-OMON59470Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vicadrostat and spironolactone in heart failure (HF), cardiac morbidity and chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in estimated glomerular filtration rate. Started Apr 2026; status: recruiting.
02
Drugs
vicadrostatspironolactone
03
Conditions
heart failure (HF)cardiac morbiditychronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON59470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59470.